Operator: Good afternoon. Thank you for attending today s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today s call.
Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment…
Moderna said a late-stage trial found that its vaccine for respiratory syncytial virus was 84% effective in preventing at least two symptoms in adults ages 60 and older.
Moderna says RSV vaccine 84% effective at preventing symptoms in older adults cbc.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cbc.ca Daily Mail and Mail on Sunday newspapers.
Moderna said on Tuesday that its experimental mRNA vaccine for respiratory syncytial virus was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.